Bionano Genomics (BNGO) Cost of Revenue (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Cost of Revenue data on file, last reported at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 2.39% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (down 34.82% YoY), and the FY2025 full-year result was $15.3 million, down 49.59% from the prior year.
• Cost of Revenue retreated to $3.4 million in Q1 2026, from $4.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.5 million in Q3 2024 to a low of $157000.0 in Q4 2024.
• A 5-year average of $5.5 million and a median of $5.2 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue tumbled 98.1% in 2024 and soared 2799.36% in 2025, its largest moves.
• Tracing BNGO's Cost of Revenue over 5 years: stood at $6.4 million in 2022, then advanced by 29.22% to $8.3 million in 2023, then plunged by 98.1% to $157000.0 in 2024, then soared by 2799.36% to $4.6 million in 2025, then retreated by 24.54% to $3.4 million in 2026.
• Business Quant data shows BNGO's Cost of Revenue at $3.4 million in Q1 2026, $4.6 million in Q4 2025, and $4.0 million in Q3 2025.